Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201612-13 Development of anti-hepatitis B virus agent(Infectious Diseases, Genetics) [2019-05-27]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Hepatitis B virus (HBV) infects approximately 400 million peoples worldwide and causes hepatitis/liver cirrhosis/liver cancer, however, there is no agents for complete cure of HBV. Therefore, the aim of this project is to develop the anti-HBV agent which can cure HBV infection.

 

Unmet Medical Need & Target Patients

This drug can be treated for all chronically infected HBV patients. Approximately, 400 million patients are target of this drug.

The current anti-HBV drugs are all nucleos(t)ide analogues which inhibit HBV RT (Reverse transcriptase)

For complete cure of HBV infection, an agent which can control HBV cccDNA, an viral reservoir, is needed.

Status

- MOA study and optimization of lead compounds.

- Non-GLP toxicology study of lead compounds.

- Validation of lead compounds using HepaRG and primary human hepatocyte (PHH).

- Validation of lead compounds mouse models.

Intellectual Property

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS B VIRUS

- Patent registered in Korea (2016)

Competitive Advantages

- Lead compounds can be applied to all genotypes of HBV.

- Lead compounds can control viral RNAs as well as cccDNA.

- Lead compounds can a first-in-class of anti-HBV agent which targets the viral cccDNA.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code